NCT00775411

Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 44 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

The study will evaluate the safety and efficacy of the intravitreal dexamethasone implant as adjunctive therapy to Anti-VEGF treatment in the study eye of treatment naïve subjects with choroidal neovascularization secondary to age-related macular degeneration. Subjects will be followed for 26 weeks.

Conditions

• Choroidal Neovascularization
• Age-Related Maculopathy

Interventions

Type	Name	Description
DRUG	dexamethasone	700 µg dexamethasone intravitreal injection at Day 1 in the study eye.
BIOLOGICAL	ranibizumab	Ranibizumab injection at Week 2 or 3 per specified criteria and starting at Week 4 at the investigator's discretion in the study eye.

Timeline

• Start date: 2008-11-01
• Primary completion: 2009-11-01
• Completion: 2010-04-01
• First posted: 2008-10-20
• Last updated: 2012-09-03
• Results posted: 2012-09-03

Locations

3 sites across 3 countries: United States, Australia, Philippines